The Law Offices of Frank R. Cruz announces an investigation of Bausch + Lomb Corporation (“BLCO” or the “Company”) (NYSE: BLCO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On March 27, 2025, BLCO disclosed that it had “[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs)” and was voluntarily recalling all of its enVista Envy and enVista Aspire IOLs, as well as enVista monofocal lenses.

On this news, BLCO’s stock price fell $1.54, or 9.8%, over two consecutive trading days to close at $14.13 per share on March 28, 2025, thereby injuring investors.

Then, on April 30, 2025, BLCO released its first quarter 2025 financial results, disclosing that “as enVista ramps back up, for the full year 2025, [it] estimate[s] one-time recall headwinds of approximately $55 million to revenue and $65 million to adjusted EBITDA.”

On this news, BLCO’s stock price fell $2.16, or 15.7%, to close at $11.56 per share on April 30, 2025, thereby injuring investors further.